FDA Advisory Panel To Evaluate Acetaminophen Pediatric Dosing
This article was originally published in The Tan Sheet
Executive Summary
FDA's pediatric and nonprescription drugs advisory committees will consider whether the agency should add dosing information for children under 2 years to labels for OTC products containing acetaminophen at a joint meeting May 17-18.
You may also be interested in...
Acetaminophen Panel To Mull Expanded Dosing, Standard Solid Concentration
FDA is asking a joint advisory panel to consider whether it should restrict firms to one standard acetaminophen concentration for all solid oral dosage single-ingredient pediatric products, among other measures to reduce dosing errors.
Acetaminophen Panel To Mull Expanded Dosing, Standard Solid Concentration
FDA is asking a joint advisory panel to consider whether it should restrict firms to one standard acetaminophen concentration for all solid oral dosage single-ingredient pediatric products, among other measures to reduce dosing errors.
Acetaminophen Panel To Mull Expanded Dosing, Standard Solid Concentration
FDA is asking a joint advisory panel to consider whether it should restrict firms to one standard acetaminophen concentration for all solid oral dosage single-ingredient pediatric products, among other measures to reduce dosing errors.